Suspended

DIABOLODBT and ACT Combined Program for Suicidal Behavior Prevention in BPD Patients

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
What is being tested

DBT+ACT

+ DBT

Behavioral
Who is being recruted

Mental Disorders

+ Borderline Personality Disorder

+ Personality Disorders

From 18 to 50 Years
+14 Eligibility Criteria
See all eligibility criteria
How is the trial designed

Prevention Study

Interventional
Study Start: November 2019
See protocol details

Summary

Principal SponsorUniversity Hospital, Montpellier
Last updated: January 28, 2026
Sourced from a government-validated database.Claim as a partner

Study start date: November 30, 2019

Actual date on which the first participant was enrolled.

This study is about finding a better way to prevent suicidal behavior in women with Borderline Personality Disorder (BPD). BPD is a condition where a person has trouble managing their emotions, often leading to suicidal thoughts. The study combines two therapies, Dialectical Behavior Therapy (DBT) and Acceptance Commitment Therapy (ACT), to help these women. DBT teaches skills in areas like managing emotions and dealing with stress, while ACT helps develop thinking skills and understanding what's important in life. The goal is to see if combining these therapies can reduce suicidal behavior, improve quality of life, and lower costs related to BPD care. Women participating in the study will have 4 visits. The first visit is for inclusion, happening 1 or 2 weeks before therapy starts, involving a clinical exam and questionnaires. The next three visits are follow-ups, happening at 6, 12, and 18 months after the first therapy session for the group receiving both DBT and ACT. These visits involve clinical exams, questionnaires, and evaluations of the therapy's effectiveness and satisfaction. The main outcome measured is the number of suicide attempts before and after therapy, using the Columbia-Suicide Severity Rating Scale.

Official TitleEfficacy of a Dialectical Behavior Therapy and Acceptance Commitment Therapy Short Program for Prevention of Suicidal Behavior in Patients With Borderline Personality Disorder
NCT03880071
Principal SponsorUniversity Hospital, Montpellier
Last updated: January 28, 2026
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.

Prevention Study

Prevention studies aim to stop a disease from developing. They often involve people at risk and test things like vaccines, lifestyle changes, or preventive medications.



Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Female

Biological sex of participants that are eligible to enroll.

From 18 to 50 Years

Range of ages for which participants are eligible to join.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

Mental DisordersBorderline Personality DisorderPersonality Disorders

Criteria

6 inclusion criteria required to participate
Being a woman

Between 18 and 50 years old

Clinical diagnosis of BPD using the Structured Clinical Interview for DSM-IV-TR ( Diagnostic and Statistical Manual of mental disorders) Axis II Personality Disorders)

Having signed the informed consent

Show More Criteria

8 exclusion criteria prevent from participating
Life time diagnosis of schizophrenia

Life time diagnosis of intellectual disability

Not able to read and write

Refusal of participation

Show More Criteria

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.
Treatment Groups
Study Objectives

2 intervention groups are designated in this study

This study does not include a placebo group 

Treatment Groups

Group I

Experimental
\- The experimental group (DBT+ ACT) led in Montpellier during 6 months.

Group II

The control group (DBT) led in Geneva during 12 months.

Study Objectives

Primary Objectives

Secondary Objectives

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 1 location

Suspended

CHU Montpellier

Montpellier, FranceOpen CHU Montpellier in Google Maps
SuspendedOne Study Center